EVA Pharma Launches the First Egyptian Generic for Type 2 Diabetes Treatment Diaflozimet® Tablets
Cairo, October 12, 2020 – EVA Pharma announced the launch of Diaflozimet® tablets after having received approval from the Egyptian Drug Authority (EDA). Diaflozimet® is the first Egyptian generic that contains (dapagliflozin and metformin hydrochloride extended-release), which is indicated for the treatment of adults with type 2 diabetes. The drug combines two anti-hyperglycemic agents with complementary mechanisms of action, dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, is a once-daily oral tablet. According to clinical studies, the combination is proven effective in rapidly controlling blood glucose levels with a 3% reduction of HbA1C, up to 3.3Kg weight reduction, blood pressure reduction and protecting the kidney, heart, blood vessels and liver against diabetes complications.
This is a very promising treatment from many aspects” said Dr. Abbas Oraby, professor of endocrinology and member of the National Committee for Endocrinology and Diabetes of the Ministry of Health and Population. “SGLT2 inhibitors release glucose from the body via the kidneys; in addition to recent studies proving its effectiveness in improving heart and kidney functions which is vital for diabetic patients since 50% of renal dialysis patients are diabetic. While metformin improves cardiac functions by 15% in addition to its abilities to lower blood glucose levels and to inhibit liver cirrhosis and the deterioration of insulin-producing beta cells in the pancreas. Thus the combination of both active ingredients supports a more personalized approach to disease management, as it reduces the number of pills the diabetic patients need to take leading to better compliance. Also, as EVA Pharma is producing Diaflozimet® in four concentrations, the physician has the choice of more personalized doses to his patients.”